Advertisement
Advertisement
MRKR
Marker Therapeutics, Inc. Common Stock
1.31
USDSponsored
-0.06
-4.38%
Jun 24, 15:54 UTC -4
Closed
After-Market
1.31
0.00
0.00%
MRKR Earnings Reports
Positive Surprise Ratio
MRKR beat 20 of 28 last estimates.
71%
Next Report
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$695.64K
/-$0.21
Implied change from Q1 26 (Revenue/ EPS)
-7.49%
/+31.25%
Implied change from Q2 25 (Revenue/ EPS)
-19.21%
/-25.00%
Marker Therapeutics, Inc. Common Stock earnings per share and revenue
On May 15, 2026, MRKR reported earnings of -0.16 USD per share (EPS) for Q1 26, beating the estimate of -0.18 USD, resulting in a 14.44% surprise. Revenue reached 752.00 thousand, compared to an expected 695.64 thousand, with a 8.10% difference. The market reacted with a -2.11% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.21 USD, with revenue projected to reach 695.64 thousand USD, implying an increase of 31.25% EPS, and decrease of -7.49% in Revenue from the last quarter.
FAQ
What were Marker Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Marker Therapeutics, Inc. Common Stock reported EPS of -$0.16, beating estimates by 14.44%, and revenue of $752.00K, 8.1% above expectations.
How did the market react to Marker Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -2.11%, changed from $1.42 before the earnings release to $1.39 the day after.
When is Marker Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Marker Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Marker Therapeutics, Inc. Common Stock is expected to report EPS of -$0.21 and revenue of $695.64K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement